AM-125 in the Treatment of Acute Peripheral Vertigo Following Vestibular Schwannoma Resection

Study Purpose

Treatment of vertigo after removal of a tumor of the balance and hearing nerve. This trial explores the efficacy and safety of AM-125 in the treatment of acute vertigo. In this proof of concept trial patients experiencing vertigo after vestibular schwannoma resection will receive AM-125 or placebo. It evaluates the potential of AM-125 versus placebo in reducing the symptoms of vestibular dysfunction and accelerating vestibular compensation following vestibular schwannoma resection.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 65 Years
Gender All
More Inclusion & Exclusion Criteria

Main

Inclusion Criteria:

1. Scheduled for vestibular schwannoma resection. 2. Small to moderately large vestibular schwannoma (Koos grade I-III; Samii grade T1-T3b; ≤ 30 mm in diameter in cerebellopontine angle) that does not compress the brainstem, documented by magnetic resonance imaging not older than six months. 3. Confirmed vestibular function on both sides Main

Exclusion Criteria:

1. Prior radiotherapy (e.g. gammaknife) affecting the brain-stem. 2. Any ongoing other peripheral vestibular disorder (e.g. Meniere's disease, benign paroxysmal vertigo, vestibular neuritis) or central vestibular disorder (e.g. vestibular migraine, central vertigo). 3. Vestibular rehabilitation therapy or gentamicin therapy within the past three months prior to VS surgery. 4. Any clinically relevant nasal obstruction or pathology precluding effective and/or safe intranasal delivery.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03908567
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Auris Medical AG
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Vestibular Vertigo
Study Website: View Trial Website
Arms & Interventions

Arms

Placebo Comparator: Placebo

Nasal spray solution without active ingredient

Experimental: 1 mg AM-125

Nasal spray solution with 5 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 3 mg betahistine dihydrochloride.

Experimental: 2.5 mg AM-125

Nasal spray solution with 12.5 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 7.5 mg betahistine dihydrochloride.

Experimental: 5 mg AM-125

Nasal spray solution with 25 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 15 mg betahistine dihydrochloride.

Experimental: 10 mg AM-125

Nasal spray solution with 50 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 30 mg betahistine dihydrochloride.

Experimental: 20 mg AM-125

Nasal spray solution with 100 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 60 mg betahistine dihydrochloride.

Experimental: Oral 16 mg betahistine

Tablets containing betahistine dihydrochloride. Administered three times daily as 1 tablet per time. Total daily dose is 48 mg oral betahistine dihydrochloride.

Interventions

Drug: - Intranasal Drug

Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day

Drug: - Oral Tablet

Oral dosing with tablets 3 times a day

Other: - Intranasal Placebo

Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

CHP Clairval, Marseille, France

Status

Recruiting

Address

CHP Clairval

Marseille, ,

Stay Informed & Connected